This symposium took place on 9th June 2016, as a part of the 21st Congress of the European Hematology Association (EHA) 2016 in Copenhagen, Denmark
Paul Richardson,1 Roman Hájek,2 Antonio Palumbo,3,4 Shaji Kumar,5 Katarina Luptakova4
1. Harvard Medical School and Dana-Farber Cancer Institute, Boston, Massachusetts, USA
2. University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic
3. University of Turin, Turin, Italy
4. Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
5. Mayo Clinic, Rochester, Minnesota, USA
Disclosure: Prof Richardson has received honoraria for scientific advisory board engagements from Celgene, Takeda Oncology, Novartis, Bristol-Myers Squibb, Genmab and Janssen, as well as research grants from Celgene and Takeda Oncology. Prof Hájek has received honoraria from Amgen, Janssen, Celgene, Takeda, and Bristol-Myers Squibb, as well as research grants from Amgen, Janssen, Celgene, and Takeda. Dr Palumbo has received honoraria from Amgen, Bristol-Myers Squibb, Genmab, Celgene, Janssen, Takeda, Onyx, Novartis, and Sanofi, as well as honoraria for consulting from Amgen, Bristol-Myers Squibb, Genmab, Celgene, Janssen, Takeda, and Onyx, and has been an employee of Takeda Oncology as of July 1st 2016. Prof Kumar has received honoraria for consulting from Takeda, Celgene, AbbVie, Janssen, Sanofi, SkylineDx, GlycoMimetics, NOXXON, and Kesios Therapeutics, as well as research grants from Takeda, Celgene, Novartis, AbbVie, Janssen, and Sanofi.
Acknowledgements: Writing assistance was provided by Mia Cahill BSc, ApotheCom.
Support: The publication of this article was funded by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. The views and opinions expressed are those of the authors and not necessarily Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Citation: EMJ Hematol. 2016;4:55-65.
The treatment landscape for patients with multiple myeloma (MM) is constantly evolving. Over the past decade, the introduction of novel agents including proteasome inhibitors (PI) and immunomodulatory agents has led to notable changes in therapeutic strategy and significant improvements in survival. Understanding this landscape and what this means in terms of translating clinical trials to everyday practice is essential.
Prof Paul Richardson opened the symposia with an introduction to currently available agents and recent developments in MM, and highlighted the importance of how we think about current studies. Prof Roman Hájek explored clonal evolution, how it can be prevented in the context of relapsed disease, and the evidence from clinical trials supporting the use of combination therapy. Dr Antonio Palumbo addressed the concept of continuous therapy in MM and where the field is at present. Prof Shaji Kumar described the early phase development of ixazomib. Prof Paul Richardson presented the results from the TOURMALINE-MM1 trial.